CA2087541A1 - Multivalent anti-cytokine immunoglobulins - Google Patents
Multivalent anti-cytokine immunoglobulinsInfo
- Publication number
- CA2087541A1 CA2087541A1 CA002087541A CA2087541A CA2087541A1 CA 2087541 A1 CA2087541 A1 CA 2087541A1 CA 002087541 A CA002087541 A CA 002087541A CA 2087541 A CA2087541 A CA 2087541A CA 2087541 A1 CA2087541 A1 CA 2087541A1
- Authority
- CA
- Canada
- Prior art keywords
- multivalent
- antigen binding
- binding domains
- cytokine
- multivalent immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A multivalent immunoglobulin which comprises at least three linked antigen binding domains each of said domains being specific for a complementary site on a cytokine, (e.g. TNF-.alpha., TNF-.beta., an interleukin, an interferon, such as IFN-.gamma., or/and a colony stimulating factor) and characteristically interacts with the cytokine to neutralise its biological activity. The multivalent immunoglobulins have suprisingly increased neutralising activity and are useful for therapeutic or prophylactic treatment of conditions involving undesirably elevated levels of the cytokine.
Preferably the multivalent immunoglobulin comprises from 4 to 20 antigen binding domains, which are especially of class IgG. The multivalent immunoglobulin may comprise recombinant immunoglobulin molecules and fragments thereof, and the antigen binding domains may be covalently or non-covalently linked.
Preferably the multivalent immunoglobulin comprises from 4 to 20 antigen binding domains, which are especially of class IgG. The multivalent immunoglobulin may comprise recombinant immunoglobulin molecules and fragments thereof, and the antigen binding domains may be covalently or non-covalently linked.
Description
2087~41 MULTIVALENT ~NTI-CYTO~INE IMMnNOGLOBULINS
., FI~LD OF TEE INVENTION
The present invention relates to multivalent anti-cytokine immunoglobulins and to their manufacture and use in therapy. In particular, the multivalent immunoglobu~ins are suitable for use in therapies requiring the neutralisation of cytokines occurring in the body at -~
deleteriously high levels.
. .
The cytokines are a group of polypeptide mediators which 0 transmit signals from one cell to another of the same or different type. As used herein the term cytokine encompasses lymphokines. For example, the anti-cytokine immunoglobulin may be an anti tumour necrosis Pactor-~
~TNF-~) or anti tumour necrosis factor-~ t~NF-~) immunoglobulin and may be employed in the reduction of - levels of TNF-~ or TNF-~ in the body.
BACl~GROU~3D OF T~IE INV~NTION
Antibodies, or immunoglobulins, are classlfied in five immunoglobulin classes, immunoglobulin G (IgG), Lmmunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin D (IgD) and immunoglobulin E (IgE).
Immunoglobulins of each of these classes comprise~a basic four chain structure of two identical light polypeptide chains and two identical heavy polypeptide chains linked together by disulphide bonds. This basic structure is hereina~ter sometimes referred to as an immunoglobulin molecule. Bach immunoglobulin class is further classified into subclasses. For example human IgG
comprises subclasses IgGl, IgG2, IgG3 and IgG4. The clas~ and subclass of an immunoglo~ulin is determined by ,~
its heavy chain type.
,, ~
WO 9;!/0147? pcrtGns1 /01216 ~7~1 IgG is the major immunoglobulin in normal human serum and is a monomer of the four chain structure described abova. IgM accounts for a smaller, but signifieGn~,, proportion of the human immunoglobulin pool and is a pentameric structure in which monomers of the our chain structure are linked by disulphide bridges between the heavy chains and by a polypeptide linker designa~ed the J
chain.
Of the other immunoglobulins, IgA is the most common and may occur in either a monomeric or dimeric form. IgD and IgE occur in very small quantities in humans and are both exclusively monomeric.
The amino terminal domains of the heavy and light chains of the basic structure are characterised by sequence ~ariability and are designated VH (variable heavy) domain and VL (variable light) domain. The VH and VL domains together form antigen binding domains of the immunoglobulin. The basic our chain immunoglobulin structure thus has two antigen binding domains.
Consequently an IgM has a total of ten antigen binding ;~
domains. It will, therefore, be apparent that immunoglobulins occurring in nature have a variety of valencies for the antigens they bind, two in the case of IgG, IgD and IgE, two or four for IgA, and ten for IgM.
In a similar way, the antigens which an antibody recognises may have one, a ew or many antigenic determinants or epitopes. The antigenic determinants o ~;
a multi determinant antigen may be the same as, or different from, one another. ~;
For example, a small molecule or hapten may have a single antigenic determinant which is recognised by a '~ ~
W092/01472 PCT/&B91/01216 . .
- 3 - ~0875~1 complementary antigen binding region of an immunoglobulin molecu}e. ~y contrast a large protein molecule may have multiple, foL example tens of, determinants on its surface.
It is already well known that the existence of antigens with multiple epitopes may lead to a bonus effect in which the binding of two antigen molecules by antibodies recognising different determinants on the antigen is always greater than the arithmetic sum of the links formed -~
by the individual antibodies. The same considerations lo are also known to apply ~o antibody binding to a polymeric antigen with the same repeating determinants. Thus the apparent avidity of the antibody - antigen interaction can be greater than the affinity of the individual antiyenic determinant - antibody binding site interactions. As one moves from a univalent Fab fragment possessing one VH and one VL domain to a divalent IgG to a pentameric IgM, the bonus effect of multivalency produces striking increases in the strength of antigen - antibody complex formation (See for example ~E~sential Immunology", I. Roitt 6th Edn ` (1988) Blackwell Scientific Publications).
.
In the course o~ comparing various monoclonal antibodies to tumour necrosis factor-~ ~anti-TNF antibodies) with the same VH domain for their ability to neutralise human recom~inant TNF we observed that an IgM antibody was significantly better than the best of the IgG antibodies tested. Furthermore, it was observed that a monoclonal IgG to recombinant TNF which had been stored for one year after manufacture and which had aggregated to higher molecular weight, inaluding dimeric and trimeric, forms displayed greater neutralisation activity than freshly manufactured monomeric antibody. Also, while the dimeric aggr~gate showed slightly better neutralisation than the " '~' ' ~,.
,, , - , , 20~75~1 monomer, the trimer gave much better neutralisation.
These observations led us to cross llnk the available IgGs. The effect of the c,oss-lin1~ing ~as to produce a multivalent immunoglobulin and bring about a surprising increase in the neutralising activity of the antibodies.
D~3SCRIPTION OF ASP~3C'rS OF T~E INVENTION
Thus, according to one aspect of the present invention there is provided a multivalent immunoglobulin co~prising at least three linked antigen binding domains each of said an igen binding domains being specific for a complementary site on a cytokine.
~.
The combined interactions between the antigen binding domains of the multivalent immunoglobulin and the complementary cytokine sites are characteristically neutralising interactions. As used herein the expression "neutralising" or ~neutralisation" means the inhibition of or reduction in a biological activity of the cytokine as measured in an in vitro or in vivo test.
Each of the at least three linked antigen binding domains are specific for the same cytokine. ~owever, different antigen binding domains in the multivalent immunoglobulin may be specific for different epitopes of the same cytokine. For example, each antigen binding region is directed to a neutralising epitope of the cytokine which it recognises. ~owever this need not be so, so long as the combined interactions of antigen bindi~g domains and comp~ementary sites are neutralising as mentioned above.
In addition to the at least three linked antigen binding domains speci~ic for the same cytokine, the multivalent immunoglobulin may include one or more other antigen binding domains specific for a further cytokine or other molecule.
,, : . .. ~ ., .. : . :~ . . ...... . . ........ . .... . .
: , :: : : : ~ : : : : . ~ : , , , :
W092fO1472 ~ a 4 ~ PCT/GB91~01216 The cytokines for which the multivalent immunoglobulins of the invention are specific are typically soluble cytokines.
Examples of cytokines for which the antibody binding domains of the multivalent immunoglobulin may be specific include tumour necrosis factor-~ (TNF-~), tumour necrosis factor-~ (TNF-~ or lymphotoxin), the interleukins (IL-l, IL-2, IL-3, IL-4, IL-5, IL-6 etc.), inter~erons (e.g.
IFN-~, IFN-~ or IFN-~) and colony stimulating factors (e.g. G-CSF, GM-CSF, etc.).
The cytokine may be monomeric and have at least two epitopic sites recognised by one or more of the antigen binding domains of the multivalent immunogIobulin.
Alternatively, the antigen binding domains of the multivalent immunoglobulin may be specific for a multimeric cytokine, such that the cytokine recognised may have at least two eFitopic sites recognised by one or more of the antigen binding domains of the multivalent immunoglobulin. The cytokine may be multimeric as a result of its aggregation or polymerisation. For example, TN~ is known to exist in oligomeric as well as monomeric forms. Thus, T~F-~ molecules associate with each other to form trimers and hence may behave as multivalent binding partners for the multivalent immunoglobulin. Interferon-y and TNF-~ may al90 exist in oligomeric forms.
The size of the multivalent immunoglobulin i5 likely to be limited by solubility considerations. Thus, the number of linked antigen binding domains is preferably sufficiently small that the multivalent immunoglobulin does not form an insoluble precipitate before it comes into contact with its complementary cytokine. The upper . .. ~ .... . . . . ... : . . . . .
WO92J014,2 PCT/GB91/01216 2~875~
limit on the number of linked antigen ~inding domains may, perhaps be as many as 4000. However, the preferred n~nber ~ F linked 2ntig~n binding domains is likely to be much smaller than that, for example in the range from 4 to 20, preferably 4 to lO antigen binding domains.
The antigen binding domains of the polymeric immunoglobulin may be derived from immunoglobulins of any class - IgG, IgM, IgA, IgD or IgE, and of any immunoglobulin subclass. The various antigen binding domains in a given polymeric immunoglobulin may be of the same or different immunoglobulin class or subclass.
Preferably, they are all oflclass IgG.
Alternatively, all antigen binding domains in the multivalent irmmunoglobulin may be derived from Ig~. In that case, the multivalent immunoglobulin differs from the native IgM molecule, for example in containing fewer than or greater than ten antigen binding domains, or in another way as will become apparent hereafter. Similarly, where the antigen binding domains are all derived from IgA the multivalent immunoglobulin differs from the native -molecule. For example, the multivalent immunoglobulin may contain three or at least five binding domains or differ in some other way from native IgA.
The antigen binding domains of the multivalent immunoglobulin may be present as part of whole immunoglobulin molecules, for example o~ a whole IgG
molecule. Alternatively, they may be part of immunoglobulin molecule fragments produced, ~or example, by enzymatic digestion o~ the intact molecule. Thus the antibody binding domains may be comprised by Fv, Fab, Fab' or F(ab') 2 fragments of IgG. Alternatively, the binding sites may be present on corresponding IgM fragments.
WO92/01472 2 0 ~ 7 ~ 4 ~ PCT/GBgl/01~16 .
The immunoglobulin molecules and ragments thereof, may be of anim~l, for example mammalian, origin and may be for example of murine, rat, or human origin/ They may be of polyclonal, but are prefera~ly of monoclonal origin. They may be prepared using well known immunological techniques.
For example, any suitable host may be injected with a cytokine and the serum collected to yield, after appropriate purification and/or concentration (for example by affinity chromatography using immobilised cytokine as the affinity medium), the desired polyclonal antibody to the cytokine. Alternatively, splenocytes or lymphocytes may be recovered from the cytokine injected host and immortalised using for example the method of Galfre, G., et al (1977), Nature 266, 550,the resulting ceIls being segregated to obtain a single genetic line producing monoclonal antibodies to the antigen in accordance with conventional practice. Antibody fragments may be produced using conventional techniques, for example by enzymatic digestion of whole antibodies e.g. with pepsin (Parham, J. Immunol., 131, 2895 (1983)) or papain (Lamoyi and Nisonoff, J. Immunol. Meth., 56, 235 (1983)).
Particuiarly useful immunoglobulins for use according to the invention include recombinant immunoglobulins and fragments thereof.
Especially useful recombinant immunoglobulins include;
(1) those having antigen binding domains at least part o~ which is derived from a different immunoglobulin, for example those in which the hypervariable or complementarity determining regions ~CDRs) of one immunoglobulin have been grafted into the variable domain framework of a second, different immunoglobulin (as described in European Patent Specification No. 239400);
WO9~/01472 PCT/GB91/01216 2~`~7~1 (2) recombinant immunoglobulins or fragments wherein non-variable domain sequences have been substituted ~y non-variable domain sequences from oth~r;
different immunoglobulins (as descrihed in European Patent Speci~ications Nos. 1206g4, 125020, 171496, 173494 and 194276); or (3) recombinant immunoglobulins or fragment~ possessing substantially the structure of a natural Lmmunoglobulin but wherein the hinge region has a 0 different number of cysteine residues from that found in the natural immunoglobulin, or wherein one or more cysteine residues in a surface pocket of the recombinant immunoglobulin or fragment is in the place of another amino acid residue present in the natural immunoglobulin (as described in published International Patent Applications Nos. WO89/01974 and WO89/01782 respectively~.
Most especially the recombinant immunoglobulins comprise humanised CDR-grafted or humanised chimeric immunoglobulins and fragments thereof.
Recombinant immunoglobulins may comprise whole immunoglobulin molecules or immunoglobulin molecule fragments, including those discussed above, as well as single chain antibodies, e.g. single chain Fvs.
zs Antigen binding domains of the multivalent immunoglobulin may be linked by means of a covalent cross-link. The cross-link may join antigen binding domains directly (for example as described in PCT/GB 90/00935 for multivalent Fvs) or,~ where an antigen binding domain is present as part of a larger immunoglobulin fragment or a whole immunoglobulin molecule then the cross-link may be remote from the antigen binding domain.
.
w092~01472 2 0 ~ 7 5 ~1 PCT/GB91/01~16 g Immunoglobulin molecules or fragments thereof which include antigen binding domains may be linked by means of a disul~hlde brldge between cysteine residues or, alternativel~t, by means of a cross-linker molecule. The -cross-linker may, generally, be one which is reactive with side chains of amino aclds in the immunoglobulin molecules or fragments to be linked. Such amlno acids preferably do not participate directly in antigen binding. Suitable amino acids for cross-linking include those wi~h a side 0 chain containing an amino, sulphydryl, carboxyl, phenolic or other aromatic or heteroaromatic functional group through which a cross-linker may be attached. Suitable amino acids include lysine, cysteine, glutamic and aspartic acids, and tyrosine. Alternatively, the components of the multivalent immunoglobulin may be linked through carbohydrate residues of the components and, in particular, thrbugh oxidised carbohydrate residues.
Suitable molecules for cross-linking immunoglobulins and other proteins are well known to those of skill in the art.
A list of suitable molecules may be found, for example, in the l989 Handbook and General Catalog Gf Pierce Chemical Company. One example of a way in which immunoglobulin molecules or fragments may be cross-linked is by reacting one component to be linked with 2-iminothiolane while activating the other with maleimide for example by reacting it with a maleimido-succinimide ester.
As an alternative to covalent linking antigen binding domains may be linked by non-covalent interactions ~or example, the link may be provided by an antibody molecule specific for sites on the immunoglobulin fragments or molecules to be cross-linked, these sites being ones which are not i~volved in antigen binding. For example where whole immunoglobulins are to be cross-linked t4ls may be WO 92/01477 2 0 ~ 7 5 ~ ~ PCr/GB91/01216 ef f ected ~y msans of an anti-Fc antibody directed to the constant region of the immunoglobulins to be linked.
An alternative way by which non-covalent cross-linking may be achieved is by biotin-avidin cross-linking in which immunoglobulin molecules or fragments derivatised with biotin are caused to aggregate through interaction with avidin.
Whatever the form of cross-linking used it i5 desirable that the antigen binding domains in the multivalent lo immunoglobulin should be in the correct orientation for ~ntigen binding.
As already mentioned preferred multivalent immunoglobulins of the present invention include linked IgG molecules and/or IgG fragments. ~owever, the multivalent immuno~lobulin may also be based on IgM molecules or fragments. For example, the multivalent immunoglobulin might be a fragment of a natural IgM for example ob~ained by partial enzymatic digestion. Alternatively, an artificial IgM might be produced by replacing the natural cross-links of the IgM with others, possibly at a different location, and such cross-links could be used to link whole IgM molecules or fragments. A further possibility is that intact IgM pentamers could be linked to form decamers and etc.
According to a second aspect of the pre~ent invention there is provided a multivalent immunoglobulin o~ the first aspect of the invention for u~e in therapy.
The therapies in which the multivalent immunoglobulin of the present invention may be utilised include any in which it is desirable to reduce the level of or inhibit the W092/0l472 % 0 8~ ~ 4~ PCT/GB91/01216 activity of cytokine present in the human or animal body. The cytokine or lymphokine may be one which is in circulation in the patient or which ls pre~nt ~. a~.
undeslrably high level localised at a particular site in 5 the body. Elevated levels of TNF-~, for example, are implicated in immunoregulatory and inflammatory disorders and in septic, or endotoxic, and cardiovascular shock. A
multivalent immunoglobulin with antigen binding domains specific for TNF-~ may be utilised in therapy of lo conditions which include: septic or endotoxic shock, cachexia, adult r~spiratory distress syndrome, AIDS, allergies, psoriasis, T.B., inflammatory bone disorders, blood coagulation disorders, burns, rejection episodes following organ or tissue transplant and autoimmune diseases e.g. organ specific diseases such as thyroiditis or non-specific organ diseases such as rheumatoid and osteo-arthritis.
Additionally, the multivalent immunoglobulin may be used to ameliorate side effects associated with ~NF generation during neoplastic therapy and also to eliminate or ameliorate shock related symptoms associated with the treatment or prevention of graft rejection by use of an antilymphocyte anti~ody.
Similarly the multivalent immunoglobulins of the invention having specificity for other cytokines, such as interferon 7, lymphotoxin, IL-i, IL-2, IL-5 and IL-6 may he used to treat conditions associated with elevated levels of the cytokine in question.
According to a third aspect of the invention there is provided the use of a multivalent immunoglobulin according to the first aspect of the invention in the manufacture of a medicament for the treatment of a condition involving WO92~014,2 PCTtGB91/01216 2 ~ 87 ~ 12 -undesirably high levels of a cytokine for which the multivalent immunoglobulin is specific. - -Preferably, the cytokine is interferon-~ (IFN-7), interleukin-l (IL-l), interleukin-2 (IL-2) interleukin-6 (IL-6), tumour necrosis factor-~ (TNF-~), or tumour necrosis factor-~ (TNF~
The medicament prepared according to the third aspect of the invention may be for administration in any appropriate form and amount according to the therapy in which it i5 employed. It may be for prophylacti~ use, for example where circumstances are such that an elevation in the level of a particular cytokine might ~e expected, or, alternatively, the medicament may be for use in reducing the level of the cytokine after it has reached an undesirably high level or as the level is rising.
According to a further aspect of the invention there is provided a pharmaceutical composition comprising a multivalent immunoglobulin according to the ~irst aspect of the invention in combination with a pharmaceutically ~?
acceptable diluent, excipient or carrier.
The composition may comprise other active ingredi`ents.
The composition may take any suitable form for administration, and, in partiaular, will be in a form suitable for parenteral administration e.g. ~y injection or infusion, for example by bolus injection or continuous infusion. Where the composition i9 for injection or infusion it may take the ~orm o~ a suspension, solution or emulsion of the multivalent immunoglobulin in an oily or agueous vehicle and it may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
' : . .
WO92~0l472 ~ 2 0 8 7541 PCT/GB91/01216 Alternatively, the composition may be in dry form, for reconstitutlon before use with an appropriate sterile liquid.
The dose at which ~he multivalent immunoglabulin will be administered will depend on the nature of the condition to be treated, the degree to which ~he cytokine to be neutralised i5, or is expected to be, rai~ed above a desirable level, on whether the multivalent Lmmunoglobulin is being used prophylac~ically or to treat an existing condition, and on the nature of the particular multivalent immunoglobulin selected for the therapy. Dose wi11 also be selected according to the age and condition of the patient.
Thus, for example, where the multivalent immunoglobulin is a conjugate of intact ~gG molecules having specificity for TNF-~, the IgG molecules being cross-linked with an anti-Fc antibody, and where the multivalent immunoglobulin is employed in the prophylaxis or treatment of TNF-~
related conditions such as shock or inflammation suita~le zo doses are in the range 0.001 to 10 mg/kg/day. The dose may be continued for as long as is necessary to alleviate the condition associated with the undesirably high level of antigen.
.
In a still further aspect of the invention there i8 provided a method of therapeutic treatment of a human or animal subject suffering ~rom a disorder associated with an undesirably high level of a cytokine, the method comprising administering to the subject an effective amount of a multivalent immunoglobulin according to the first aspect of the invention.
' WO92Jo1472 PCT/GB91/01216 20~7~ 14 In another aspect ~f the invention there is provided a process for the production of a multiva}ent immunoglobulin of the f rst aspect of the invention said me_h5d comprising linking the immunoglobulin molecules or fragments thereof by means of a suitable linker. ~
Suitable linkers have already been mentioned above. It -will therefore be understood that linking may be effected by reacting immunoglobulin molecules or fragments with a covalent cross-linker or by bringing them into contact with an antibody or other aggregating agent to effect non-covalent cross-linking.
Also in the case of recombinant immunoglobulins, processes for the production of the multivalent immunoglobulins will involve expression of immunoglobulin molecules or ~ragments in appropriate host cells transformed with suitable DNA sequences.
BRI13F Dl~SCRIP~l!ION OF ~ FIGURES
The invention is described below by way of example with reference to the following figures of which:
.
Figure 1 is a plot of residual bioactive T~F-~
activity after antibody treatment against initial concentration of anti-TNF antibody for 4 different antibodies designated 129/16, ;'' lOl/4, CB6 and 27/26;
Figure 2 is a ~ketch showing ~he manner in which anti-TNF antibodies may be linked by means of an anti-Fc (it will be appreciated that the array, illustrated in two dimensions is, in fact, three dimensional);
.
., FI~LD OF TEE INVENTION
The present invention relates to multivalent anti-cytokine immunoglobulins and to their manufacture and use in therapy. In particular, the multivalent immunoglobu~ins are suitable for use in therapies requiring the neutralisation of cytokines occurring in the body at -~
deleteriously high levels.
. .
The cytokines are a group of polypeptide mediators which 0 transmit signals from one cell to another of the same or different type. As used herein the term cytokine encompasses lymphokines. For example, the anti-cytokine immunoglobulin may be an anti tumour necrosis Pactor-~
~TNF-~) or anti tumour necrosis factor-~ t~NF-~) immunoglobulin and may be employed in the reduction of - levels of TNF-~ or TNF-~ in the body.
BACl~GROU~3D OF T~IE INV~NTION
Antibodies, or immunoglobulins, are classlfied in five immunoglobulin classes, immunoglobulin G (IgG), Lmmunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin D (IgD) and immunoglobulin E (IgE).
Immunoglobulins of each of these classes comprise~a basic four chain structure of two identical light polypeptide chains and two identical heavy polypeptide chains linked together by disulphide bonds. This basic structure is hereina~ter sometimes referred to as an immunoglobulin molecule. Bach immunoglobulin class is further classified into subclasses. For example human IgG
comprises subclasses IgGl, IgG2, IgG3 and IgG4. The clas~ and subclass of an immunoglo~ulin is determined by ,~
its heavy chain type.
,, ~
WO 9;!/0147? pcrtGns1 /01216 ~7~1 IgG is the major immunoglobulin in normal human serum and is a monomer of the four chain structure described abova. IgM accounts for a smaller, but signifieGn~,, proportion of the human immunoglobulin pool and is a pentameric structure in which monomers of the our chain structure are linked by disulphide bridges between the heavy chains and by a polypeptide linker designa~ed the J
chain.
Of the other immunoglobulins, IgA is the most common and may occur in either a monomeric or dimeric form. IgD and IgE occur in very small quantities in humans and are both exclusively monomeric.
The amino terminal domains of the heavy and light chains of the basic structure are characterised by sequence ~ariability and are designated VH (variable heavy) domain and VL (variable light) domain. The VH and VL domains together form antigen binding domains of the immunoglobulin. The basic our chain immunoglobulin structure thus has two antigen binding domains.
Consequently an IgM has a total of ten antigen binding ;~
domains. It will, therefore, be apparent that immunoglobulins occurring in nature have a variety of valencies for the antigens they bind, two in the case of IgG, IgD and IgE, two or four for IgA, and ten for IgM.
In a similar way, the antigens which an antibody recognises may have one, a ew or many antigenic determinants or epitopes. The antigenic determinants o ~;
a multi determinant antigen may be the same as, or different from, one another. ~;
For example, a small molecule or hapten may have a single antigenic determinant which is recognised by a '~ ~
W092/01472 PCT/&B91/01216 . .
- 3 - ~0875~1 complementary antigen binding region of an immunoglobulin molecu}e. ~y contrast a large protein molecule may have multiple, foL example tens of, determinants on its surface.
It is already well known that the existence of antigens with multiple epitopes may lead to a bonus effect in which the binding of two antigen molecules by antibodies recognising different determinants on the antigen is always greater than the arithmetic sum of the links formed -~
by the individual antibodies. The same considerations lo are also known to apply ~o antibody binding to a polymeric antigen with the same repeating determinants. Thus the apparent avidity of the antibody - antigen interaction can be greater than the affinity of the individual antiyenic determinant - antibody binding site interactions. As one moves from a univalent Fab fragment possessing one VH and one VL domain to a divalent IgG to a pentameric IgM, the bonus effect of multivalency produces striking increases in the strength of antigen - antibody complex formation (See for example ~E~sential Immunology", I. Roitt 6th Edn ` (1988) Blackwell Scientific Publications).
.
In the course o~ comparing various monoclonal antibodies to tumour necrosis factor-~ ~anti-TNF antibodies) with the same VH domain for their ability to neutralise human recom~inant TNF we observed that an IgM antibody was significantly better than the best of the IgG antibodies tested. Furthermore, it was observed that a monoclonal IgG to recombinant TNF which had been stored for one year after manufacture and which had aggregated to higher molecular weight, inaluding dimeric and trimeric, forms displayed greater neutralisation activity than freshly manufactured monomeric antibody. Also, while the dimeric aggr~gate showed slightly better neutralisation than the " '~' ' ~,.
,, , - , , 20~75~1 monomer, the trimer gave much better neutralisation.
These observations led us to cross llnk the available IgGs. The effect of the c,oss-lin1~ing ~as to produce a multivalent immunoglobulin and bring about a surprising increase in the neutralising activity of the antibodies.
D~3SCRIPTION OF ASP~3C'rS OF T~E INVENTION
Thus, according to one aspect of the present invention there is provided a multivalent immunoglobulin co~prising at least three linked antigen binding domains each of said an igen binding domains being specific for a complementary site on a cytokine.
~.
The combined interactions between the antigen binding domains of the multivalent immunoglobulin and the complementary cytokine sites are characteristically neutralising interactions. As used herein the expression "neutralising" or ~neutralisation" means the inhibition of or reduction in a biological activity of the cytokine as measured in an in vitro or in vivo test.
Each of the at least three linked antigen binding domains are specific for the same cytokine. ~owever, different antigen binding domains in the multivalent immunoglobulin may be specific for different epitopes of the same cytokine. For example, each antigen binding region is directed to a neutralising epitope of the cytokine which it recognises. ~owever this need not be so, so long as the combined interactions of antigen bindi~g domains and comp~ementary sites are neutralising as mentioned above.
In addition to the at least three linked antigen binding domains speci~ic for the same cytokine, the multivalent immunoglobulin may include one or more other antigen binding domains specific for a further cytokine or other molecule.
,, : . .. ~ ., .. : . :~ . . ...... . . ........ . .... . .
: , :: : : : ~ : : : : . ~ : , , , :
W092fO1472 ~ a 4 ~ PCT/GB91~01216 The cytokines for which the multivalent immunoglobulins of the invention are specific are typically soluble cytokines.
Examples of cytokines for which the antibody binding domains of the multivalent immunoglobulin may be specific include tumour necrosis factor-~ (TNF-~), tumour necrosis factor-~ (TNF-~ or lymphotoxin), the interleukins (IL-l, IL-2, IL-3, IL-4, IL-5, IL-6 etc.), inter~erons (e.g.
IFN-~, IFN-~ or IFN-~) and colony stimulating factors (e.g. G-CSF, GM-CSF, etc.).
The cytokine may be monomeric and have at least two epitopic sites recognised by one or more of the antigen binding domains of the multivalent immunogIobulin.
Alternatively, the antigen binding domains of the multivalent immunoglobulin may be specific for a multimeric cytokine, such that the cytokine recognised may have at least two eFitopic sites recognised by one or more of the antigen binding domains of the multivalent immunoglobulin. The cytokine may be multimeric as a result of its aggregation or polymerisation. For example, TN~ is known to exist in oligomeric as well as monomeric forms. Thus, T~F-~ molecules associate with each other to form trimers and hence may behave as multivalent binding partners for the multivalent immunoglobulin. Interferon-y and TNF-~ may al90 exist in oligomeric forms.
The size of the multivalent immunoglobulin i5 likely to be limited by solubility considerations. Thus, the number of linked antigen binding domains is preferably sufficiently small that the multivalent immunoglobulin does not form an insoluble precipitate before it comes into contact with its complementary cytokine. The upper . .. ~ .... . . . . ... : . . . . .
WO92J014,2 PCT/GB91/01216 2~875~
limit on the number of linked antigen ~inding domains may, perhaps be as many as 4000. However, the preferred n~nber ~ F linked 2ntig~n binding domains is likely to be much smaller than that, for example in the range from 4 to 20, preferably 4 to lO antigen binding domains.
The antigen binding domains of the polymeric immunoglobulin may be derived from immunoglobulins of any class - IgG, IgM, IgA, IgD or IgE, and of any immunoglobulin subclass. The various antigen binding domains in a given polymeric immunoglobulin may be of the same or different immunoglobulin class or subclass.
Preferably, they are all oflclass IgG.
Alternatively, all antigen binding domains in the multivalent irmmunoglobulin may be derived from Ig~. In that case, the multivalent immunoglobulin differs from the native IgM molecule, for example in containing fewer than or greater than ten antigen binding domains, or in another way as will become apparent hereafter. Similarly, where the antigen binding domains are all derived from IgA the multivalent immunoglobulin differs from the native -molecule. For example, the multivalent immunoglobulin may contain three or at least five binding domains or differ in some other way from native IgA.
The antigen binding domains of the multivalent immunoglobulin may be present as part of whole immunoglobulin molecules, for example o~ a whole IgG
molecule. Alternatively, they may be part of immunoglobulin molecule fragments produced, ~or example, by enzymatic digestion o~ the intact molecule. Thus the antibody binding domains may be comprised by Fv, Fab, Fab' or F(ab') 2 fragments of IgG. Alternatively, the binding sites may be present on corresponding IgM fragments.
WO92/01472 2 0 ~ 7 ~ 4 ~ PCT/GBgl/01~16 .
The immunoglobulin molecules and ragments thereof, may be of anim~l, for example mammalian, origin and may be for example of murine, rat, or human origin/ They may be of polyclonal, but are prefera~ly of monoclonal origin. They may be prepared using well known immunological techniques.
For example, any suitable host may be injected with a cytokine and the serum collected to yield, after appropriate purification and/or concentration (for example by affinity chromatography using immobilised cytokine as the affinity medium), the desired polyclonal antibody to the cytokine. Alternatively, splenocytes or lymphocytes may be recovered from the cytokine injected host and immortalised using for example the method of Galfre, G., et al (1977), Nature 266, 550,the resulting ceIls being segregated to obtain a single genetic line producing monoclonal antibodies to the antigen in accordance with conventional practice. Antibody fragments may be produced using conventional techniques, for example by enzymatic digestion of whole antibodies e.g. with pepsin (Parham, J. Immunol., 131, 2895 (1983)) or papain (Lamoyi and Nisonoff, J. Immunol. Meth., 56, 235 (1983)).
Particuiarly useful immunoglobulins for use according to the invention include recombinant immunoglobulins and fragments thereof.
Especially useful recombinant immunoglobulins include;
(1) those having antigen binding domains at least part o~ which is derived from a different immunoglobulin, for example those in which the hypervariable or complementarity determining regions ~CDRs) of one immunoglobulin have been grafted into the variable domain framework of a second, different immunoglobulin (as described in European Patent Specification No. 239400);
WO9~/01472 PCT/GB91/01216 2~`~7~1 (2) recombinant immunoglobulins or fragments wherein non-variable domain sequences have been substituted ~y non-variable domain sequences from oth~r;
different immunoglobulins (as descrihed in European Patent Speci~ications Nos. 1206g4, 125020, 171496, 173494 and 194276); or (3) recombinant immunoglobulins or fragment~ possessing substantially the structure of a natural Lmmunoglobulin but wherein the hinge region has a 0 different number of cysteine residues from that found in the natural immunoglobulin, or wherein one or more cysteine residues in a surface pocket of the recombinant immunoglobulin or fragment is in the place of another amino acid residue present in the natural immunoglobulin (as described in published International Patent Applications Nos. WO89/01974 and WO89/01782 respectively~.
Most especially the recombinant immunoglobulins comprise humanised CDR-grafted or humanised chimeric immunoglobulins and fragments thereof.
Recombinant immunoglobulins may comprise whole immunoglobulin molecules or immunoglobulin molecule fragments, including those discussed above, as well as single chain antibodies, e.g. single chain Fvs.
zs Antigen binding domains of the multivalent immunoglobulin may be linked by means of a covalent cross-link. The cross-link may join antigen binding domains directly (for example as described in PCT/GB 90/00935 for multivalent Fvs) or,~ where an antigen binding domain is present as part of a larger immunoglobulin fragment or a whole immunoglobulin molecule then the cross-link may be remote from the antigen binding domain.
.
w092~01472 2 0 ~ 7 5 ~1 PCT/GB91/01~16 g Immunoglobulin molecules or fragments thereof which include antigen binding domains may be linked by means of a disul~hlde brldge between cysteine residues or, alternativel~t, by means of a cross-linker molecule. The -cross-linker may, generally, be one which is reactive with side chains of amino aclds in the immunoglobulin molecules or fragments to be linked. Such amlno acids preferably do not participate directly in antigen binding. Suitable amino acids for cross-linking include those wi~h a side 0 chain containing an amino, sulphydryl, carboxyl, phenolic or other aromatic or heteroaromatic functional group through which a cross-linker may be attached. Suitable amino acids include lysine, cysteine, glutamic and aspartic acids, and tyrosine. Alternatively, the components of the multivalent immunoglobulin may be linked through carbohydrate residues of the components and, in particular, thrbugh oxidised carbohydrate residues.
Suitable molecules for cross-linking immunoglobulins and other proteins are well known to those of skill in the art.
A list of suitable molecules may be found, for example, in the l989 Handbook and General Catalog Gf Pierce Chemical Company. One example of a way in which immunoglobulin molecules or fragments may be cross-linked is by reacting one component to be linked with 2-iminothiolane while activating the other with maleimide for example by reacting it with a maleimido-succinimide ester.
As an alternative to covalent linking antigen binding domains may be linked by non-covalent interactions ~or example, the link may be provided by an antibody molecule specific for sites on the immunoglobulin fragments or molecules to be cross-linked, these sites being ones which are not i~volved in antigen binding. For example where whole immunoglobulins are to be cross-linked t4ls may be WO 92/01477 2 0 ~ 7 5 ~ ~ PCr/GB91/01216 ef f ected ~y msans of an anti-Fc antibody directed to the constant region of the immunoglobulins to be linked.
An alternative way by which non-covalent cross-linking may be achieved is by biotin-avidin cross-linking in which immunoglobulin molecules or fragments derivatised with biotin are caused to aggregate through interaction with avidin.
Whatever the form of cross-linking used it i5 desirable that the antigen binding domains in the multivalent lo immunoglobulin should be in the correct orientation for ~ntigen binding.
As already mentioned preferred multivalent immunoglobulins of the present invention include linked IgG molecules and/or IgG fragments. ~owever, the multivalent immuno~lobulin may also be based on IgM molecules or fragments. For example, the multivalent immunoglobulin might be a fragment of a natural IgM for example ob~ained by partial enzymatic digestion. Alternatively, an artificial IgM might be produced by replacing the natural cross-links of the IgM with others, possibly at a different location, and such cross-links could be used to link whole IgM molecules or fragments. A further possibility is that intact IgM pentamers could be linked to form decamers and etc.
According to a second aspect of the pre~ent invention there is provided a multivalent immunoglobulin o~ the first aspect of the invention for u~e in therapy.
The therapies in which the multivalent immunoglobulin of the present invention may be utilised include any in which it is desirable to reduce the level of or inhibit the W092/0l472 % 0 8~ ~ 4~ PCT/GB91/01216 activity of cytokine present in the human or animal body. The cytokine or lymphokine may be one which is in circulation in the patient or which ls pre~nt ~. a~.
undeslrably high level localised at a particular site in 5 the body. Elevated levels of TNF-~, for example, are implicated in immunoregulatory and inflammatory disorders and in septic, or endotoxic, and cardiovascular shock. A
multivalent immunoglobulin with antigen binding domains specific for TNF-~ may be utilised in therapy of lo conditions which include: septic or endotoxic shock, cachexia, adult r~spiratory distress syndrome, AIDS, allergies, psoriasis, T.B., inflammatory bone disorders, blood coagulation disorders, burns, rejection episodes following organ or tissue transplant and autoimmune diseases e.g. organ specific diseases such as thyroiditis or non-specific organ diseases such as rheumatoid and osteo-arthritis.
Additionally, the multivalent immunoglobulin may be used to ameliorate side effects associated with ~NF generation during neoplastic therapy and also to eliminate or ameliorate shock related symptoms associated with the treatment or prevention of graft rejection by use of an antilymphocyte anti~ody.
Similarly the multivalent immunoglobulins of the invention having specificity for other cytokines, such as interferon 7, lymphotoxin, IL-i, IL-2, IL-5 and IL-6 may he used to treat conditions associated with elevated levels of the cytokine in question.
According to a third aspect of the invention there is provided the use of a multivalent immunoglobulin according to the first aspect of the invention in the manufacture of a medicament for the treatment of a condition involving WO92~014,2 PCTtGB91/01216 2 ~ 87 ~ 12 -undesirably high levels of a cytokine for which the multivalent immunoglobulin is specific. - -Preferably, the cytokine is interferon-~ (IFN-7), interleukin-l (IL-l), interleukin-2 (IL-2) interleukin-6 (IL-6), tumour necrosis factor-~ (TNF-~), or tumour necrosis factor-~ (TNF~
The medicament prepared according to the third aspect of the invention may be for administration in any appropriate form and amount according to the therapy in which it i5 employed. It may be for prophylacti~ use, for example where circumstances are such that an elevation in the level of a particular cytokine might ~e expected, or, alternatively, the medicament may be for use in reducing the level of the cytokine after it has reached an undesirably high level or as the level is rising.
According to a further aspect of the invention there is provided a pharmaceutical composition comprising a multivalent immunoglobulin according to the ~irst aspect of the invention in combination with a pharmaceutically ~?
acceptable diluent, excipient or carrier.
The composition may comprise other active ingredi`ents.
The composition may take any suitable form for administration, and, in partiaular, will be in a form suitable for parenteral administration e.g. ~y injection or infusion, for example by bolus injection or continuous infusion. Where the composition i9 for injection or infusion it may take the ~orm o~ a suspension, solution or emulsion of the multivalent immunoglobulin in an oily or agueous vehicle and it may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
' : . .
WO92~0l472 ~ 2 0 8 7541 PCT/GB91/01216 Alternatively, the composition may be in dry form, for reconstitutlon before use with an appropriate sterile liquid.
The dose at which ~he multivalent immunoglabulin will be administered will depend on the nature of the condition to be treated, the degree to which ~he cytokine to be neutralised i5, or is expected to be, rai~ed above a desirable level, on whether the multivalent Lmmunoglobulin is being used prophylac~ically or to treat an existing condition, and on the nature of the particular multivalent immunoglobulin selected for the therapy. Dose wi11 also be selected according to the age and condition of the patient.
Thus, for example, where the multivalent immunoglobulin is a conjugate of intact ~gG molecules having specificity for TNF-~, the IgG molecules being cross-linked with an anti-Fc antibody, and where the multivalent immunoglobulin is employed in the prophylaxis or treatment of TNF-~
related conditions such as shock or inflammation suita~le zo doses are in the range 0.001 to 10 mg/kg/day. The dose may be continued for as long as is necessary to alleviate the condition associated with the undesirably high level of antigen.
.
In a still further aspect of the invention there i8 provided a method of therapeutic treatment of a human or animal subject suffering ~rom a disorder associated with an undesirably high level of a cytokine, the method comprising administering to the subject an effective amount of a multivalent immunoglobulin according to the first aspect of the invention.
' WO92Jo1472 PCT/GB91/01216 20~7~ 14 In another aspect ~f the invention there is provided a process for the production of a multiva}ent immunoglobulin of the f rst aspect of the invention said me_h5d comprising linking the immunoglobulin molecules or fragments thereof by means of a suitable linker. ~
Suitable linkers have already been mentioned above. It -will therefore be understood that linking may be effected by reacting immunoglobulin molecules or fragments with a covalent cross-linker or by bringing them into contact with an antibody or other aggregating agent to effect non-covalent cross-linking.
Also in the case of recombinant immunoglobulins, processes for the production of the multivalent immunoglobulins will involve expression of immunoglobulin molecules or ~ragments in appropriate host cells transformed with suitable DNA sequences.
BRI13F Dl~SCRIP~l!ION OF ~ FIGURES
The invention is described below by way of example with reference to the following figures of which:
.
Figure 1 is a plot of residual bioactive T~F-~
activity after antibody treatment against initial concentration of anti-TNF antibody for 4 different antibodies designated 129/16, ;'' lOl/4, CB6 and 27/26;
Figure 2 is a ~ketch showing ~he manner in which anti-TNF antibodies may be linked by means of an anti-Fc (it will be appreciated that the array, illustrated in two dimensions is, in fact, three dimensional);
.
4~2 2 a ~ 75~ ~ PCTtGB91/01216 `- 15 -Figures show plots of residual bioactive TNF-~ after 3~5 antibody txeatment against initial concentration of anti-TNF for three anti-TNF
antibodies (lOl/4, HTNFl and CB6) which were cross-linked with a polyclonal anti-Fc;
Figure 6 shows a plot of TNF-~ activity remaining after antibody treatment agains~
concentration of biotinylated CB6 antibody cross-linked with avidin; ~-Figure 7 compares the neutralisin~ efficiency of a biotinylated anti-lymphotoxin antibody (hLTl2 Biotin) to the same antibody after avidin ``
cross-linking (hLTl2 Biotin:Avidin l:l);
Figure 8 shows a plot G~ TNF ~ activity remaining after antibody treatment against concentration of CB6 antibody which has been covalently cross-linked;
Figure 9 .i9 a plasmid diagram of plasmid pE2056 containing the human C~ coding sequence, and Figure lO shows plots of residual bioactive TNF-~ after antibody treatment against initial concentration of anti-TNF for IgG and IgM
versions of the antibody lOl/4; numerals 2-5 re~er to four separate sample~ of lOl/4 IgM.
..... .. . . . .
WOg2/0l~72 PCT/GB91/~1216 ~a~7~ 16 -D~SCRIPTION OF SPECIFIC ENBODIM~NTS OF TE~ INVENTION
Com~arative Exam~le~ IqG and IqM
Antibodies 129/16 and 101/4 are murine monoclonal antibodies of immunoglobulin class IgG raised against recombinant human TNF-~ and obtained from the National Institute for Biological Standards and Controls (NIBSC).
CB6 and HTNFl are also murine monoclonal IgG to .
recombinant human TNF-~ and were produced at Celltech. ~;
lo Antibody 27/26 is a murine monoclonal IgM against TNF-~ ~
and was obtained from NIBSC. ~:
`.
Comparison of Neutralisinq ActivitY of IqGs and IqM
The neutralising activity of various antibodies was compared using an L929 bioassay as descxibed by Ruff and Gifford, ~ymphokines 2 235 (1981). Briefly, it was ~ `
carried out as follows. `~
L929 cells were prepared for use in the following way.
The supernatant medium was removed from L929 cells which were growing as an adherent monolayer in RPMI 1640 medium :;
tGibco) containing 2mM ~lutamine 10~ FCS, and lOO~g/ml gentam1cin (RP10). The monolayer was washed in Dulbecco~s A phosphate buffered saline (PBS) (Gibco).
Trypsin EDTA (Cibco) was added for 10 min to remove cells from the plastic and the cell suspen9ion was then added to RP10 medium at a ~inal density of 3 x 106 viable aells/ml ~, as assessed by Trypan Blue (Gibco) dye exclusion. 100 of this cell suspension was then added to each weLl of flat-bottomed 96-well microtitre trays (Falcon Microtest) and incubated over-night at 37~C.
-'.`` .' .'.' ~,'.,..,:
W092~01472 2 0 8 7 ~ ~ ~ PC~/GB91/01216 Dilutions of the antibodies to be tested were prepared in assay medium (RPMI 1640 containing glutamine, gentamicin and 2% FCS 1% actinomycin D~. Dilu~ions ~f hwman recom~inant TNF-~ (NIBSC standard) were also made up in assay medium then added to all dilutions.
The L929 assay was subsequently carried out as follows:
Microtitre plates containing the L929 cells were flicked to remove the RPMI 1640 medium. lOO~l of the antibody -and TNF dilutions were dispensed to the appropriate wells of the microtitre plates. Control wells containing assay medium and antibodies at the highest concentration were added. The plates were then incubated overnight at 37C.
After the overnight incubation, the L929 plates were flicked to remove the medium and were washed once carefully in PBS. Methanol (AnalaR) was then added to all wells and left for 30-60 seconds. The methanol was then flicked off, a solution of crystal violet (1% w/v in water) was added to all the wells and incubated for 5 mins. This was then washed off with tap water and the stain then dissolved in the well in lOO~l of 30% glacial acetic acid (AnalaR). Absorbance was measured at 570nm and the absorbance at 4lOnm was used as a reference measurement to correct for light scatter.
Live L929 cells take up crystal violet while those killed by TNF do not. In experiments where the amount of TNF
added to the wells is kept constant and the antibody concentration is varied the absorbance of the extracted stain may therefore be used as a measure of the TNF
available in solution for killing L929 cells.
WO92/01472 PCT/GB91/012l6 ~ ~ 8 ~ ~1 18 The results of the experiment in which antibodies 129/16, lOl/4, CB6 and 27/26 were compared are shown in Figure 1.
Irl this case tll~ concentration of TNF in each well was 400pg/ml which i~ sufficient to effect almost total cell killing; the concentration o~ the various anti~TNF ~ ?
antibodies varied from well to well.
It is apparent from the results shown that significantly greater amounts of the IgG antibodies than o~ the IgM
antibodies were required to neutralise the same amount of TNF-~. Thus for example where the starting concentration of TNF-~ was 400pg/ml the ID~o (the concentration of antibody that gave 50% inhibition) was 3.4ng/ml for the IgM antibody 27/26, whereas the ID50s for the IgG
antibodies were 55ng/ml for 129/16, 42ng/ml for CB6 and llng/ml for 101/4.
Thus, it is clear that the IgM antibody has a significantly higher neutralising activity than corresponding IgGs.
In order to establish whether the increased neutralising activity of the IgM was a result of the cross-linking of the immunoglobulin units various IgGs were cross-linked and the effect on their neutralising activities ;-investigated. ``
.'`' I .
"', WO92/0l~72 2 Q 8 7 ~ ~1 PCT/ÇB91/01216 -- 19 ,- ., Example ~
Cross-linkin~ Antibodies Usinq Anti-Fc Selected IgGs were cross-llnked using a polyclonal anti-Fc antibody (Jacksons Labs) specific for the constant region of the murine IgG molecule. The anti-Fc antibody has the effect of cross-linking the IgG~s by their Fc regions leaving their binding domains available for antigen binding. The manner of binding is repre~ented in Figure 2 in which IgG anti-TNF molecules 1 are arranged in an array linked at the N terminal ends 3 of their constant regions 5 by anti-Fc antibody molecules 7. TNF molecules 9 are shown bound at the antibody binding sites at the C
terminal ends 11 of the anti-TNF molecules 1. From 2 up to around 2000 anti-TNF molecules may be cross-linked together in this way.
The following procedure was used to effect the cross-linking.
Separate solutions o each antibody to be tested together with goat [F(ab')2~ anti-mouse IgG-Fc in L929 assay medium were made up to a concentration of 2~g/ml antibody and 20~g/ml anti-Fc. Up to nine, three-fold dilutions of the antibody-anti-Fc mixtures were prepared and the dilutions incubated at 37C for 1 hour.
The neutralising activity of the cross-linked antibodies was assessed using an L929 bioassay as described abo~e.
100~1 of each of the antibody - anti-Fc mixture and of TNF
being dispensed into the appropriate wells of a microtitre ~`
tray. The concentration of TNF in each well was 400pg/ml as before.
The effect of the cross-linking is demonstrated in Figures 3-5 in which TNF remaining available for cell killing is WO92tO1472 PCT/GB91/01216 2 0~ 7 ~ ~ l ~ 20 -plotted against antibody dilution for each o~ the IgG
antibodies lOl/4, HTNFl and CB6. In each case measurements were made for the an.i~ody a ~n~ o~ 1~Tlth added anti-Fc. Anti-Fc alone was shown to have no effect.
:.
Figure 3, for example, shows the effect of adding anti-Fc antibody to the anti TNF antibody lOl/4. It is apparent `~
from this plot that for a given antibody dilution more TNF
is neutralised in the presence than in the ab~ence of cross-linking by anti-Fc.
Similar effects are demonstrated in Figures 4 and 5 for the antibodies HTNFl and CBÇ respectively. It is noteworthy that the poorer the neutralising activity of the antibody in the absence of anti-Fc the greater the improvement in ~eutralising activity which can be brought about by the addition of the anti-Fc antibody.
I'able l below summarises the effect of polyclonal anti-Fc on TNF neutralisation by each of the antibodies lOl/44, HTNFl and CB6. In each case neutralisation was improved to an efficacy that is close to he theoretical maximum, i.e. a molar excess of antibody to antig~n of 0.5-l.
WO92/01472 20875~1 PCT/GB91/01216 - 2l -Tabie I
Summary Table showing effect of a polyclonal anti-Fc on efficacy of anti-TNF antibodies in TNF neutrallsation ~:~
Anti-TNF Anti-TNF Fold :~
Alone + Anti-Fc Improvement Molar excess of antibody required for ~O~ inh~ A ~e ~
1~1/4 1.3 0.3 4.3 ~ :
~.
HTNF 7 l 7 ~.
, C96 60 0.4 150 W092/~14~2 PCT/GB91/01216 2~ 1 22 - ~
~xample 3 Cross-Llnkln~ Anti~odies usinq Biotin-Avidin [a] Anti-TNF antibody CB~ was biotinylated accordin~ to conventional procedure as described, for example, in Practical Immunology~ L. Hudson and F.C. Hay, 3rd Edn, 1989, ~lackwell Scientific Publications.
'~
~iotin labelled antibody was mixed with streptavidin ~Jackson Labs) at molar ratios of lO~ l and 1:10, and then incubated at 37C or lhr to form complexes. Three fold serial dilutions of the biotin labelled antibody and of the complexes were prepared in L929 assay medium and the L929 assay ;;
carried out as de~cribed above. ~-' ~ ,, The results are shown in Figure 6 from which it is apparent that where biotinylated CB6 and avidin were complexed in a l:l ratio the neutralising activity of the antibody was significantly increased relati~e ~, to uncompLexed biotinylated antibody or to complexes farmed with lO:l or l:lO ratios of biotinylated antibody to avidin.
[b~ The experiment in Part [a] was repeated using a ~
biotinylated anti-lymphotoxin antibody (hLTl2) ``
cross-linked with avidin at a molar ration of l~
The results are shown in Figure 7 from which it is apparent that the neutralising activity of the cross-linked antibody was significantly increased relative to uncomplexed biotinylated antibody.
.
W092/01472 2 a g 7 5 ~1 PCT/~B91/01216 xam~le 4 Chemical Cross~Linkinq of Antibodies Chemically cross-linked CB6 was prepa:r-d as ~ ws:
l.65mg of CB6 (5mg/ml in PBS) was incubated with 3.2mg of 2-iminothiolane in lml of ethanol with gentle agitation for 30 minutes at room temperature.
4.75mg of CB6 (5mg/ml in PBS) was incubated with O.l95mg maleimidohexanoyl succinimide ester, with gentle agitation for 45 minutes at room temperature.
In each case excess reactants were removed by chromatography on a PDlO column.
The iminothiolane and maleimido derivatives of CB6 were then reacted together at a ratio of l:l by incubation together at room temperature for two hours.
Ethyl malemide in DMS0 was then added to each incubation `
to give a final concentration of O.Olmg/ml. `
The reaction products were subjected to HPLC, the absorbance of the fractions at 280nm being used to l~cate protein containing fractions. Selected column fractions were pooled and employed in L929 assays, as described previously.
' .
The results of the cross-linking experiments are shown in Figure 8. Fraction #6 corresponds to the monomer and Fractions ~5 to ~l contain complexed antibady o increasing molecular weight. ~Fraction #7 is smaller than the monomer and probably represents an antigen binding degradation product.] It is apparent that, in general, chemicaL cross-linking of the antibody molecules results in an enhancement of the neutralising activity of the antibody.
WO92/01472 PC~/GB91/01216 208~
Example S
Preparation of recombinant chimeric IqM
In ~ further experiment recombinant chimeric IgM ant -TL~'~
antibodies were prepared and tested for their ability to neutralise TNF in the L929 bioassay.
DNA coding for the light and heavy chain variable domains of the murine IgG anti-TNF antibody lOl.4 were ligated with DNA coding for human R light chain constant region and human ~ heavy chain constant region tc~3 respectively.
Construction of IqM versions of 101.4 ~ea w Chain . .
~uman C~ DNA was obtained as a XbaI fragment (Ward, C.J.
et al (l989) International Immunology 1, No. 3, 296-309) `
in which the coding sequences are arranged as shown in the following restriction map. ;
:., XbaI XbaI
~ C~l C~2 C~3 C~4 n n n n ~ ;
Poly A
The XbaI fragment was cloned into the Xba site of pEE7.~CMV [Stephens, P and Cockett, M.I. in Nucl. Acid.
Re~. 17, 7110 ~l989)] to produce plasmid pE2056 as shown in Figure 9. pE2056 has a unique restriction site for the enzyme Bsu 361 located at the start of C~l. The re~evant sequence is shown below.
WO92tOl472 2 ~ 8 PCT/GB9t/012t6 - ~5 -..
ssu 36I
G S A S ;~
:
intron < _ ~ C~1 'rhus pE2056 was digested with HindIII and Bsu 36I and the larger fragment ligated with a ~indIII-Bsu 36I fragment comprisi~g the coding sequence of the heavy chain variable domain of 101.4 to produce the following sequence across the V-C~l junction of the new genes. ;
GGG, ACT, CTG, GTC, ACT, GTC, TCC, TCA,I GGG, AGT, GCA, TCC
.
G T L V T V S S I G S A S ` .
101.4VH < I > C~l . .
...
This procedure generated four plasmids (which should be identicàl) which were isolated and designated pE2058-pE2061 inclusive. In Figure lO samples 2-5 correspond to results obtained using plasmids pE2058-pE2061 respectively.
Similarly a chimeric 101.4 variable-human ~ constant light chain was prepared and inserted into a suita~le expression plasmid (substantially as described in co-pending British Patent Application 9109645.3J. COS cells were lS transfected with the gene coding for the chimeric light chain together with pE2058, pE2059, pE2060 and pE2061 each in turn. COS cell supernatants were assayed in the L929 -~, ~
WOgV01~72 PCT/GB91/01216 20~75~ 26 ~
bioassay and the a~ility of the resultant recombinant chimeric "IgM" immunoglobulins to neutralise TNF compared with that of murine 101.4. Th~ resul~ obt~ined are given graphically in Fi.gure lO indicating that lower amounts of the recombinant chimeric "IgM" product than the murine IgG product were required for neutralisation of TNF.
:
The foregoing examples are given to illustrate the - invention. It will be appreciated that other monoclonal antibodies to TNF and antibodies to other cytokines in general may be used for preparation of multivalent immunoglobulins according to the invention by alternative methods as well as by loosely following the general procedure set out above.
antibodies (lOl/4, HTNFl and CB6) which were cross-linked with a polyclonal anti-Fc;
Figure 6 shows a plot of TNF-~ activity remaining after antibody treatment agains~
concentration of biotinylated CB6 antibody cross-linked with avidin; ~-Figure 7 compares the neutralisin~ efficiency of a biotinylated anti-lymphotoxin antibody (hLTl2 Biotin) to the same antibody after avidin ``
cross-linking (hLTl2 Biotin:Avidin l:l);
Figure 8 shows a plot G~ TNF ~ activity remaining after antibody treatment against concentration of CB6 antibody which has been covalently cross-linked;
Figure 9 .i9 a plasmid diagram of plasmid pE2056 containing the human C~ coding sequence, and Figure lO shows plots of residual bioactive TNF-~ after antibody treatment against initial concentration of anti-TNF for IgG and IgM
versions of the antibody lOl/4; numerals 2-5 re~er to four separate sample~ of lOl/4 IgM.
..... .. . . . .
WOg2/0l~72 PCT/GB91/~1216 ~a~7~ 16 -D~SCRIPTION OF SPECIFIC ENBODIM~NTS OF TE~ INVENTION
Com~arative Exam~le~ IqG and IqM
Antibodies 129/16 and 101/4 are murine monoclonal antibodies of immunoglobulin class IgG raised against recombinant human TNF-~ and obtained from the National Institute for Biological Standards and Controls (NIBSC).
CB6 and HTNFl are also murine monoclonal IgG to .
recombinant human TNF-~ and were produced at Celltech. ~;
lo Antibody 27/26 is a murine monoclonal IgM against TNF-~ ~
and was obtained from NIBSC. ~:
`.
Comparison of Neutralisinq ActivitY of IqGs and IqM
The neutralising activity of various antibodies was compared using an L929 bioassay as descxibed by Ruff and Gifford, ~ymphokines 2 235 (1981). Briefly, it was ~ `
carried out as follows. `~
L929 cells were prepared for use in the following way.
The supernatant medium was removed from L929 cells which were growing as an adherent monolayer in RPMI 1640 medium :;
tGibco) containing 2mM ~lutamine 10~ FCS, and lOO~g/ml gentam1cin (RP10). The monolayer was washed in Dulbecco~s A phosphate buffered saline (PBS) (Gibco).
Trypsin EDTA (Cibco) was added for 10 min to remove cells from the plastic and the cell suspen9ion was then added to RP10 medium at a ~inal density of 3 x 106 viable aells/ml ~, as assessed by Trypan Blue (Gibco) dye exclusion. 100 of this cell suspension was then added to each weLl of flat-bottomed 96-well microtitre trays (Falcon Microtest) and incubated over-night at 37~C.
-'.`` .' .'.' ~,'.,..,:
W092~01472 2 0 8 7 ~ ~ ~ PC~/GB91/01216 Dilutions of the antibodies to be tested were prepared in assay medium (RPMI 1640 containing glutamine, gentamicin and 2% FCS 1% actinomycin D~. Dilu~ions ~f hwman recom~inant TNF-~ (NIBSC standard) were also made up in assay medium then added to all dilutions.
The L929 assay was subsequently carried out as follows:
Microtitre plates containing the L929 cells were flicked to remove the RPMI 1640 medium. lOO~l of the antibody -and TNF dilutions were dispensed to the appropriate wells of the microtitre plates. Control wells containing assay medium and antibodies at the highest concentration were added. The plates were then incubated overnight at 37C.
After the overnight incubation, the L929 plates were flicked to remove the medium and were washed once carefully in PBS. Methanol (AnalaR) was then added to all wells and left for 30-60 seconds. The methanol was then flicked off, a solution of crystal violet (1% w/v in water) was added to all the wells and incubated for 5 mins. This was then washed off with tap water and the stain then dissolved in the well in lOO~l of 30% glacial acetic acid (AnalaR). Absorbance was measured at 570nm and the absorbance at 4lOnm was used as a reference measurement to correct for light scatter.
Live L929 cells take up crystal violet while those killed by TNF do not. In experiments where the amount of TNF
added to the wells is kept constant and the antibody concentration is varied the absorbance of the extracted stain may therefore be used as a measure of the TNF
available in solution for killing L929 cells.
WO92/01472 PCT/GB91/012l6 ~ ~ 8 ~ ~1 18 The results of the experiment in which antibodies 129/16, lOl/4, CB6 and 27/26 were compared are shown in Figure 1.
Irl this case tll~ concentration of TNF in each well was 400pg/ml which i~ sufficient to effect almost total cell killing; the concentration o~ the various anti~TNF ~ ?
antibodies varied from well to well.
It is apparent from the results shown that significantly greater amounts of the IgG antibodies than o~ the IgM
antibodies were required to neutralise the same amount of TNF-~. Thus for example where the starting concentration of TNF-~ was 400pg/ml the ID~o (the concentration of antibody that gave 50% inhibition) was 3.4ng/ml for the IgM antibody 27/26, whereas the ID50s for the IgG
antibodies were 55ng/ml for 129/16, 42ng/ml for CB6 and llng/ml for 101/4.
Thus, it is clear that the IgM antibody has a significantly higher neutralising activity than corresponding IgGs.
In order to establish whether the increased neutralising activity of the IgM was a result of the cross-linking of the immunoglobulin units various IgGs were cross-linked and the effect on their neutralising activities ;-investigated. ``
.'`' I .
"', WO92/0l~72 2 Q 8 7 ~ ~1 PCT/ÇB91/01216 -- 19 ,- ., Example ~
Cross-linkin~ Antibodies Usinq Anti-Fc Selected IgGs were cross-llnked using a polyclonal anti-Fc antibody (Jacksons Labs) specific for the constant region of the murine IgG molecule. The anti-Fc antibody has the effect of cross-linking the IgG~s by their Fc regions leaving their binding domains available for antigen binding. The manner of binding is repre~ented in Figure 2 in which IgG anti-TNF molecules 1 are arranged in an array linked at the N terminal ends 3 of their constant regions 5 by anti-Fc antibody molecules 7. TNF molecules 9 are shown bound at the antibody binding sites at the C
terminal ends 11 of the anti-TNF molecules 1. From 2 up to around 2000 anti-TNF molecules may be cross-linked together in this way.
The following procedure was used to effect the cross-linking.
Separate solutions o each antibody to be tested together with goat [F(ab')2~ anti-mouse IgG-Fc in L929 assay medium were made up to a concentration of 2~g/ml antibody and 20~g/ml anti-Fc. Up to nine, three-fold dilutions of the antibody-anti-Fc mixtures were prepared and the dilutions incubated at 37C for 1 hour.
The neutralising activity of the cross-linked antibodies was assessed using an L929 bioassay as described abo~e.
100~1 of each of the antibody - anti-Fc mixture and of TNF
being dispensed into the appropriate wells of a microtitre ~`
tray. The concentration of TNF in each well was 400pg/ml as before.
The effect of the cross-linking is demonstrated in Figures 3-5 in which TNF remaining available for cell killing is WO92tO1472 PCT/GB91/01216 2 0~ 7 ~ ~ l ~ 20 -plotted against antibody dilution for each o~ the IgG
antibodies lOl/4, HTNFl and CB6. In each case measurements were made for the an.i~ody a ~n~ o~ 1~Tlth added anti-Fc. Anti-Fc alone was shown to have no effect.
:.
Figure 3, for example, shows the effect of adding anti-Fc antibody to the anti TNF antibody lOl/4. It is apparent `~
from this plot that for a given antibody dilution more TNF
is neutralised in the presence than in the ab~ence of cross-linking by anti-Fc.
Similar effects are demonstrated in Figures 4 and 5 for the antibodies HTNFl and CBÇ respectively. It is noteworthy that the poorer the neutralising activity of the antibody in the absence of anti-Fc the greater the improvement in ~eutralising activity which can be brought about by the addition of the anti-Fc antibody.
I'able l below summarises the effect of polyclonal anti-Fc on TNF neutralisation by each of the antibodies lOl/44, HTNFl and CB6. In each case neutralisation was improved to an efficacy that is close to he theoretical maximum, i.e. a molar excess of antibody to antig~n of 0.5-l.
WO92/01472 20875~1 PCT/GB91/01216 - 2l -Tabie I
Summary Table showing effect of a polyclonal anti-Fc on efficacy of anti-TNF antibodies in TNF neutrallsation ~:~
Anti-TNF Anti-TNF Fold :~
Alone + Anti-Fc Improvement Molar excess of antibody required for ~O~ inh~ A ~e ~
1~1/4 1.3 0.3 4.3 ~ :
~.
HTNF 7 l 7 ~.
, C96 60 0.4 150 W092/~14~2 PCT/GB91/01216 2~ 1 22 - ~
~xample 3 Cross-Llnkln~ Anti~odies usinq Biotin-Avidin [a] Anti-TNF antibody CB~ was biotinylated accordin~ to conventional procedure as described, for example, in Practical Immunology~ L. Hudson and F.C. Hay, 3rd Edn, 1989, ~lackwell Scientific Publications.
'~
~iotin labelled antibody was mixed with streptavidin ~Jackson Labs) at molar ratios of lO~ l and 1:10, and then incubated at 37C or lhr to form complexes. Three fold serial dilutions of the biotin labelled antibody and of the complexes were prepared in L929 assay medium and the L929 assay ;;
carried out as de~cribed above. ~-' ~ ,, The results are shown in Figure 6 from which it is apparent that where biotinylated CB6 and avidin were complexed in a l:l ratio the neutralising activity of the antibody was significantly increased relati~e ~, to uncompLexed biotinylated antibody or to complexes farmed with lO:l or l:lO ratios of biotinylated antibody to avidin.
[b~ The experiment in Part [a] was repeated using a ~
biotinylated anti-lymphotoxin antibody (hLTl2) ``
cross-linked with avidin at a molar ration of l~
The results are shown in Figure 7 from which it is apparent that the neutralising activity of the cross-linked antibody was significantly increased relative to uncomplexed biotinylated antibody.
.
W092/01472 2 a g 7 5 ~1 PCT/~B91/01216 xam~le 4 Chemical Cross~Linkinq of Antibodies Chemically cross-linked CB6 was prepa:r-d as ~ ws:
l.65mg of CB6 (5mg/ml in PBS) was incubated with 3.2mg of 2-iminothiolane in lml of ethanol with gentle agitation for 30 minutes at room temperature.
4.75mg of CB6 (5mg/ml in PBS) was incubated with O.l95mg maleimidohexanoyl succinimide ester, with gentle agitation for 45 minutes at room temperature.
In each case excess reactants were removed by chromatography on a PDlO column.
The iminothiolane and maleimido derivatives of CB6 were then reacted together at a ratio of l:l by incubation together at room temperature for two hours.
Ethyl malemide in DMS0 was then added to each incubation `
to give a final concentration of O.Olmg/ml. `
The reaction products were subjected to HPLC, the absorbance of the fractions at 280nm being used to l~cate protein containing fractions. Selected column fractions were pooled and employed in L929 assays, as described previously.
' .
The results of the cross-linking experiments are shown in Figure 8. Fraction #6 corresponds to the monomer and Fractions ~5 to ~l contain complexed antibady o increasing molecular weight. ~Fraction #7 is smaller than the monomer and probably represents an antigen binding degradation product.] It is apparent that, in general, chemicaL cross-linking of the antibody molecules results in an enhancement of the neutralising activity of the antibody.
WO92/01472 PC~/GB91/01216 208~
Example S
Preparation of recombinant chimeric IqM
In ~ further experiment recombinant chimeric IgM ant -TL~'~
antibodies were prepared and tested for their ability to neutralise TNF in the L929 bioassay.
DNA coding for the light and heavy chain variable domains of the murine IgG anti-TNF antibody lOl.4 were ligated with DNA coding for human R light chain constant region and human ~ heavy chain constant region tc~3 respectively.
Construction of IqM versions of 101.4 ~ea w Chain . .
~uman C~ DNA was obtained as a XbaI fragment (Ward, C.J.
et al (l989) International Immunology 1, No. 3, 296-309) `
in which the coding sequences are arranged as shown in the following restriction map. ;
:., XbaI XbaI
~ C~l C~2 C~3 C~4 n n n n ~ ;
Poly A
The XbaI fragment was cloned into the Xba site of pEE7.~CMV [Stephens, P and Cockett, M.I. in Nucl. Acid.
Re~. 17, 7110 ~l989)] to produce plasmid pE2056 as shown in Figure 9. pE2056 has a unique restriction site for the enzyme Bsu 361 located at the start of C~l. The re~evant sequence is shown below.
WO92tOl472 2 ~ 8 PCT/GB9t/012t6 - ~5 -..
ssu 36I
G S A S ;~
:
intron < _ ~ C~1 'rhus pE2056 was digested with HindIII and Bsu 36I and the larger fragment ligated with a ~indIII-Bsu 36I fragment comprisi~g the coding sequence of the heavy chain variable domain of 101.4 to produce the following sequence across the V-C~l junction of the new genes. ;
GGG, ACT, CTG, GTC, ACT, GTC, TCC, TCA,I GGG, AGT, GCA, TCC
.
G T L V T V S S I G S A S ` .
101.4VH < I > C~l . .
...
This procedure generated four plasmids (which should be identicàl) which were isolated and designated pE2058-pE2061 inclusive. In Figure lO samples 2-5 correspond to results obtained using plasmids pE2058-pE2061 respectively.
Similarly a chimeric 101.4 variable-human ~ constant light chain was prepared and inserted into a suita~le expression plasmid (substantially as described in co-pending British Patent Application 9109645.3J. COS cells were lS transfected with the gene coding for the chimeric light chain together with pE2058, pE2059, pE2060 and pE2061 each in turn. COS cell supernatants were assayed in the L929 -~, ~
WOgV01~72 PCT/GB91/01216 20~75~ 26 ~
bioassay and the a~ility of the resultant recombinant chimeric "IgM" immunoglobulins to neutralise TNF compared with that of murine 101.4. Th~ resul~ obt~ined are given graphically in Fi.gure lO indicating that lower amounts of the recombinant chimeric "IgM" product than the murine IgG product were required for neutralisation of TNF.
:
The foregoing examples are given to illustrate the - invention. It will be appreciated that other monoclonal antibodies to TNF and antibodies to other cytokines in general may be used for preparation of multivalent immunoglobulins according to the invention by alternative methods as well as by loosely following the general procedure set out above.
Claims (15)
1. A multivalent immunoglobulin comprising at least three linked antigen binding domains each of said domains being specific for a complementary site on a cytokine.
2. A multivalent immunoglobulin according to Claim 1 in which the combined interactions between the antigen binding domains of the immunoglobulin and the complementary cytokine sites are neutralising interactions.
3. A multivalent immunoglobulin according to Claim 1 or 2 which is specific for TNF-.alpha., TNF-.beta., an interleukin, an interferon, or a colony stimulating factor.
4. A multivalent immunoglobulin according to any one of the preceding claims which has specificity for a cytokine which is naturally present as a multimer.
5. A multivalent immunoglobulin according to any one of the preceding claims comprising 4 to 20 antigen binding domains.
6. A multivalent immunoglobulin according to any one of the preceding claims in which the antigen binding domains are all of class IgG.
7. A multivalent immunoglobulin according to any one of Claims 1 - 5 in which the antigen binding domains are all of class IgM and differs from a native IgM
molecule.
molecule.
8. A multivalent immunoglobulin according to any one of the preceding claims comprising recombinant immunoglobulins and fragments thereof.
9. A multivalent immunoglobulin according to any one of the preceding claims in which antigen binding domains are linked by covalent cross-links.
10. A multivalent immunoglobulin according to any one of Claims 1 - 8, in which antigen binding domains are linked by non-covalent interactions.
11. A multivalent immunoglobulin according to Claim 1 for use in therapy.
12. The use of a multivalent immunoglobulin according to Claim 1 in the manufacture of a medicament for the treatment of a condition involving undesirably high levels of a cytokine for which the multivalent immunoglobulin in specific.
13. A pharmaceutical composition comprising a multivalent immunoglobulin according to Claim 1, in combination with a pharmaceutically acceptable diluent, excipient or carrier.
14. A method of therapeutic treatment of a human or animal subject suffering from a disorder associated with an undesirably high level of a cytokine, comprising administering to the subject an effective amount of a multivalent immunoglobulin according to Claim 1.
15. A process for the production of a multivalent immunoglobulin according to Claim 1 comprising linking the immunoglobulin molecules or fragments thereof together by means of a suitable linker.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909015908A GB9015908D0 (en) | 1990-07-19 | 1990-07-19 | Multivalent immunoglobulin |
| GB9015908.8 | 1990-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2087541A1 true CA2087541A1 (en) | 1992-01-20 |
Family
ID=10679355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002087541A Abandoned CA2087541A1 (en) | 1990-07-19 | 1991-07-19 | Multivalent anti-cytokine immunoglobulins |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0539455A1 (en) |
| JP (1) | JPH06501840A (en) |
| KR (1) | KR930701192A (en) |
| AU (1) | AU8238191A (en) |
| CA (1) | CA2087541A1 (en) |
| GB (2) | GB9015908D0 (en) |
| WO (1) | WO1992001472A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5478753A (en) * | 1993-06-29 | 1995-12-26 | Pb Diagnostic Systems, Inc. | Positive calibrator/control composition for an IgM serology assay and an IgM serology assay |
| FR2707882B1 (en) * | 1993-07-23 | 1997-08-01 | Immunotech Sa | New protein anti-mediator therapeutic kits, preparation process and pharmaceutical compositions containing them. |
| GB2281300A (en) * | 1993-08-26 | 1995-03-01 | Merck & Co Inc | Anti-HIV antibody oligomer |
| CA2195665A1 (en) * | 1994-07-22 | 1996-02-08 | Robert Frederick Geoffrey Booth | Pharmaceutical compositions comprising a chimaeric tnf binding protein |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| PT942740E (en) | 1996-12-06 | 2004-01-30 | Amgen Inc | COMBINATION THERAPY USING A TNF LIGACTION PROTEIN FOR TREATMENT OF TNF-MEDIATED DISEASES |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2001037874A2 (en) * | 1999-11-24 | 2001-05-31 | Centocor, Inc. | Treatment of psoriasis by using an antibody to tnf alpha |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| EP3247728B1 (en) | 2015-01-20 | 2020-04-15 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| EP3340995A4 (en) | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| EP3340998B1 (en) * | 2015-08-28 | 2023-01-11 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0347057A1 (en) * | 1988-05-31 | 1989-12-20 | Schering Biotech Corporation | Method of treating myeloid leukemias |
| WO1990001950A1 (en) * | 1988-08-19 | 1990-03-08 | Celltech Limited | Pharmaceutical products for anti-neoplastic therapy |
| KR900701825A (en) * | 1988-08-19 | 1990-12-04 | 로버트 에이. 아미테이지 | Lenin inhibitory peptides containing sulfeptanic acid or derivatives thereof |
| FR2640146B1 (en) * | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | ANTI-INTERLEUKIN MONOCLONAL ANTIBODIES 1 (ALPHA) AND 1 (BETA), THEIR PRODUCTION METHOD AND APPLICATIONS OF SAID ANTIBODIES TO DETECTION OF INTERLEUKINS 1 (ALPHA) AND 1 (BETA) AND THERAPEUTICS |
| FR2640143B1 (en) * | 1988-12-13 | 1991-03-15 | Maes Ludo | POLYMERIZED ANTIBODIES, DIRECTED AGAINST IMMUNOGLOBULINS - THEIR USE IN DIAGNOSTIC TESTS |
| WO1991006305A1 (en) * | 1989-11-07 | 1991-05-16 | Bristol-Myers Squibb Company | Oligomeric immunoglobulins |
-
1990
- 1990-07-19 GB GB909015908A patent/GB9015908D0/en active Pending
-
1991
- 1991-07-19 WO PCT/GB1991/001216 patent/WO1992001472A1/en not_active Application Discontinuation
- 1991-07-19 CA CA002087541A patent/CA2087541A1/en not_active Abandoned
- 1991-07-19 AU AU82381/91A patent/AU8238191A/en not_active Abandoned
- 1991-07-19 JP JP3512563A patent/JPH06501840A/en active Pending
- 1991-07-19 EP EP91913265A patent/EP0539455A1/en not_active Withdrawn
- 1991-07-19 KR KR1019930700150A patent/KR930701192A/en not_active Application Discontinuation
-
1993
- 1993-01-19 GB GB9300960A patent/GB2261666B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992001472A1 (en) | 1992-02-06 |
| EP0539455A1 (en) | 1993-05-05 |
| GB2261666B (en) | 1994-07-27 |
| KR930701192A (en) | 1993-06-11 |
| GB9300960D0 (en) | 1993-03-17 |
| GB2261666A (en) | 1993-05-26 |
| AU8238191A (en) | 1992-02-18 |
| JPH06501840A (en) | 1994-03-03 |
| GB9015908D0 (en) | 1990-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2087541A1 (en) | Multivalent anti-cytokine immunoglobulins | |
| TWI608015B (en) | Anti-inflammatory molecules with tissue-targeting functions | |
| US20230303718A1 (en) | Modified Antibody | |
| EP0574395B1 (en) | Cytokine immunoconjugates | |
| JP4257030B2 (en) | peptide | |
| CA2269115C (en) | Monovalent antibody fragments | |
| US6830752B2 (en) | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders | |
| JP2912618B2 (en) | Recombinant DNA product and production method | |
| US20030139575A1 (en) | Cytokine immunoconjugates | |
| RU2001104893A (en) | Human IgG / rodent anti-CD3 hybrid antibody and methods for its construction | |
| CA2420231A1 (en) | Antibodies to human il-1.beta. | |
| JP2007515493A (en) | Method for generating multimeric molecules | |
| EP0936923A1 (en) | SUPPRESSION OF TNF $g(a) AND IL-12 IN THERAPY | |
| JP6825033B2 (en) | BAFF and B7RP1 specific proteins and their use | |
| BRPI1013341B1 (en) | SINGLE VARIABLE DOMAIN VARIANTS OF SERUM ANTI-ALBUMINE IMMUNOGLOBULIN, MULTISPECIFIC LINKER AND COMPOSITION INCLUDING SUCH VARIANTS, AS WELL AS NUCLEIC ACIDS AND VECTOR | |
| JP5352761B2 (en) | Antibody disulfide isomers, their use and methods of analysis | |
| JP4418745B2 (en) | Antibody PEG regioisomer, composition containing same and use thereof | |
| JP2005529154A5 (en) | ||
| JPH08509963A (en) | Composition containing IgG antibody 3 | |
| JPH07562B2 (en) | Monoclonal antibody against interleukin-2 receptor | |
| JP2006505497A5 (en) | ||
| Waldmann et al. | The interleukin-2 receptor: a target for immunotherapy | |
| Moriarty | Continuing education in immunology. I: the structure and function ol immunoglobulins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |